Discounted Cash Flow Rating

Buy

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Strong Buy

Price to Earnings Rating

Strong Buy

Analyst Rating

Buy

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Buy

Standard Deviation

Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Buy

A

PDS Biotechnology Corporation Common Stock (PDSB)

Pharmaceutical Preparations

https://www.pdsbiotech.com

PDS Biotechnology Corp operates as a clinical-stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.

303A COLLEGE ROAD EAST
PRINCETON, NJ

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

10/01/2015

Market Cap

118,191,558

Shares Outstanding

31,110,000

Weighted SO

31,107,763

Total Employees

N/A

Upcoming Earnings

08/12/2024

Similar Tickers

MREO --.--%

TERN --.--%

INZY --.--%

HOOK --.--%

EFTR --.--%

ENVB --.--%

CWBR --.--%

OCEA --.--%

Beta

1.9130

Last Div

0.0000

Range

2.53-6.85

Chg

-0.0200

Avg Vol

510791

Mkt Cap

118191558

Exch

NASDAQ

Country

US

Phone

800 208 3343

DCF Diff

2.0982

DCF

1.0568

Div Yield

0.0000

P/S

0.0000

EV Multiple

-2.1388

P/FV

3.8097

Div Yield %

0.0000

P/E

-2.8955

PEG

-1.0351

Payout

0.0000

Current Ratio

3.8381

Quick Ratio

3.8381

Cash Ratio

3.6832

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

20348.6202

CCC

0.0000

Gross Margin

0.0000

Op Margin

0.0000

Pretax Margin

0.0000

Net Margin

0.0000

Eff Tax Rate

0.0210

ROA

-0.6724

ROE

-1.3706

ROCE

-0.8859

NI/EBT

0.9791

EBT/EBIT

1.0463

EBIT/Rev

0.0000

Debt Ratio

0.4014

D/E

0.7855

LT Debt/Cap

0.3088

Total Debt/Cap

0.4399

Int Coverage

0.0335

CF/Debt

-1.4177

Equity Multi

1.9567

Rec Turnover

0.0000

Pay Turnover

0.0179

Inv Turnover

0.0000

FA Turnover

0.0000

Asset Turnover

0.0000

OCF/Share

-0.9383

FCF/Share

-0.9391

Cash/Share

1.5734

OCF/Sales

0.0000

FCF/OCF

1.0008

CF Coverage

-1.4177

ST Coverage

-3.2868

CapEx Coverage

-1187.2548

Div&CapEx Cov

-1187.2548

P/BV

3.8097

P/B

3.8097

P/S

0.0000

P/E

-2.8955

P/FCF

-3.4300

P/OCF

-3.4211

P/CF

-3.4211

PEG

-1.0351

P/S

0.0000

EV Multiple

-2.1388

P/FV

3.8097

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jan 22, 16:45 PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical Officer GlobeNewswire Inc. Jan 22, 16:45 PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical Officer GlobeNewswire Inc. Dec 04, 16:50 PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. Dec 04, 16:50 PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. Nov 28, 07:30 PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer Benzinga Nov 15, 14:01 Analyst Expectations for PDS Biotechnology's Future GlobeNewswire Inc. Nov 14, 07:30 PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update

Revenue Product Segmentation